Herve Barjat

Macclesfield, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

High-resolution 3D visualization of nanomedicine distribution in tumors.

High-resolution 3D visualization of nanomedicine distribution in tumors.

Journal: Theranostics

Published: May 31, 2019

Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours?

Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours?

Journal: Magnetic resonance imaging

Published: July 12, 2017

The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.

The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.

Journal: PloS one

Published: May 04, 2017

The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor.

The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor.

Journal: EJNMMI research

Published: April 20, 2016

The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model.

The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model.

Journal: Molecular imaging and biology

Published: August 16, 2015

Quantitative correlation at the molecular level of tumor response to docetaxel by multimodal diffusion-weighted magnetic resonance imaging and [¹⁸F]FDG/[¹⁸F]FLT positron emission tomography.

Quantitative correlation at the molecular level of tumor response to docetaxel by multimodal diffusion-weighted magnetic resonance imaging and [¹⁸F]FDG/[¹⁸F]FLT positron emission tomography.

Journal: Molecular imaging

Published: November 29, 2014

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

Journal: British journal of cancer

Published: April 25, 2013

Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma.

Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma.

Journal: Magnetic resonance in medicine

Published: November 27, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026